Arbutus Biopharma (ABUS) Total Non-Current Liabilities (2011 - 2026)
Arbutus Biopharma (ABUS) posted Total Non-Current Liabilities of $8.4 million for Q1 2026, down 13.1% sequentially from $9.6 million in Q4 2025, and down 69.33% YoY from $27.3 million in Q1 2025.
Arbutus Biopharma (ABUS) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Arbutus Biopharma has reported Total Non-Current Liabilities for 16 years, with the latest figure at $8.4 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 69.33% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 69.33% YoY) and the FY2025 annual result came in at $9.6 million, down 60.0% from the prior year.
- Total Non-Current Liabilities fell to $8.4 million in Q1 2026 per ABUS's latest filing, from $9.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $55.6 million in Q1 2022 and troughed at $8.4 million in Q1 2026.
- A 5-year average of $29.5 million and a median of $29.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities jumped 336.88% in 2022, then tumbled 69.33% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $48.2 million in 2022, then sank by 36.14% to $30.8 million in 2023, then fell by 21.66% to $24.1 million in 2024, then tumbled by 60.0% to $9.6 million in 2025, then declined by 13.1% to $8.4 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $8.4 million, $9.6 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 6.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.48 Mn |
| Mar 31, 2026 | 8.38 Mn |
| Dec 31, 2025 | 9.65 Mn |
| Sep 30, 2025 | 9.21 Mn |
| Jun 30, 2025 | 9.49 Mn |
| Mar 31, 2025 | 27.33 Mn |
| Dec 31, 2024 | 24.12 Mn |
| Sep 30, 2024 | 25.22 Mn |
| Jun 30, 2024 | 29.60 Mn |
| Mar 31, 2024 | 27.87 Mn |
| Dec 31, 2023 | 30.78 Mn |
| Sep 30, 2023 | 31.19 Mn |
| Jun 30, 2023 | 33.34 Mn |
| Mar 31, 2023 | 37.93 Mn |
| Dec 31, 2022 | 48.20 Mn |
| Sep 30, 2022 | 45.97 Mn |
| Jun 30, 2022 | 48.46 Mn |
| Mar 31, 2022 | 55.59 Mn |
| Dec 31, 2021 | 18.75 Mn |
| Sep 30, 2021 | 17.57 Mn |